Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia
ConclusionSimultaneous administration of quizartinib and CYT every other day is a promising combination regimen for AML patients with FLT3 mutations.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Leukemia